A Randomized, Double-Blind, Placebo- and OMV-Controlled Phase I Study to Evaluate the Safety, Tolerance, and Immunogenicity of the Avacc 10 Vaccine Administered Intranasally to Healthy Adult Volunteers
Latest Information Update: 05 Jul 2026
At a glance
- Drugs Avacc 10 (Primary) ; OMV
- Indications COVID 2019 infections
- Focus Adverse reactions; First in man
- Acronyms ITV2002
- Sponsors Intravacc
Most Recent Events
- 30 Jun 2026 According to an AdJane media release, company announces the publication of first-in-human Phase I clinical data in the peer-reviewed journal Vaccines.
- 30 Jun 2026 Results presented in the AdJane Media Release.
- 26 Mar 2024 Results presented in an Intravacc media release.